Management of Type 2 Diabetes with Achieved Glycemic Control

Glycemic Targets and Monitoring

The American Diabetes Association recommends an HbA1c target of <7.0% for most patients with type 2 diabetes to reduce microvascular complications 1, 2, 3
Guidelines recommend maintaining fasting glucose <7.2 mmol/L (130 mg/dL) 3
Postprandial targets should be <10 mmol/L (180 mg/dL) 3
The American College of Physicians explicitly recommends considering deintensification when HbA1c falls below 6.5%, as no trials demonstrate clinical benefit from targeting levels this low, and the ACCORD trial showed increased mortality with HbA1c targets <6.5% 4

Reassess in 3 months and add a second agent only if HbA1c rises above 7.0% 1, 2, 6
For HbA1c 7.0-9.0%: Add one agent from sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP-1 receptor agonist, TZD, or basal insulin based on patient factors including cardiovascular disease, heart failure, chronic kidney disease, hypoglycemia risk, weight concerns, and cost 1, 2, 6
For HbA1c ≥9.0%: Consider initial dual combination therapy or basal insulin to more rapidly achieve glycemic control 1, 2, 6

Recheck HbA1c in 3 months to ensure maintenance of glycemic control 2, 6
Continue emphasizing lifestyle modifications including physical activity (at least 150 minutes/week) and weight management, as these remain foundational even when pharmacologic targets are met 2, 5
Monitor for metformin-related vitamin B12 deficiency with periodic measurement, especially given the patient's renal function is normal and metformin can be safely continued 1